Cargando…

Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders

The therapeutic benefits of the current medications for patients with psychiatric disorders contrast with a great variety of adverse effects. The endocannabinoid system (ECS) components have gained high interest as potential new targets for treating psychiatry diseases because of their neuromodulato...

Descripción completa

Detalles Bibliográficos
Autores principales: Navarro, Daniela, Gasparyan, Ani, Navarrete, Francisco, Torregrosa, Abraham B., Rubio, Gabriel, Marín-Mayor, Marta, Acosta, Gabriela B., Garcia-Gutiérrez, Maria Salud, Manzanares, Jorge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9104141/
https://www.ncbi.nlm.nih.gov/pubmed/35563156
http://dx.doi.org/10.3390/ijms23094764
_version_ 1784707722293280768
author Navarro, Daniela
Gasparyan, Ani
Navarrete, Francisco
Torregrosa, Abraham B.
Rubio, Gabriel
Marín-Mayor, Marta
Acosta, Gabriela B.
Garcia-Gutiérrez, Maria Salud
Manzanares, Jorge
author_facet Navarro, Daniela
Gasparyan, Ani
Navarrete, Francisco
Torregrosa, Abraham B.
Rubio, Gabriel
Marín-Mayor, Marta
Acosta, Gabriela B.
Garcia-Gutiérrez, Maria Salud
Manzanares, Jorge
author_sort Navarro, Daniela
collection PubMed
description The therapeutic benefits of the current medications for patients with psychiatric disorders contrast with a great variety of adverse effects. The endocannabinoid system (ECS) components have gained high interest as potential new targets for treating psychiatry diseases because of their neuromodulator role, which is essential to understanding the regulation of many brain functions. This article reviewed the molecular alterations in ECS occurring in different psychiatric conditions. The methods used to identify alterations in the ECS were also described. We used a translational approach. The animal models reproducing some behavioral and/or neurochemical aspects of psychiatric disorders and the molecular alterations in clinical studies in post-mortem brain tissue or peripheral tissues were analyzed. This article reviewed the most relevant ECS changes in prevalent psychiatric diseases such as mood disorders, schizophrenia, autism, attentional deficit, eating disorders (ED), and addiction. The review concludes that clinical research studies are urgently needed for two different purposes: (1) To identify alterations of the ECS components potentially useful as new biomarkers relating to a specific disease or condition, and (2) to design new therapeutic targets based on the specific alterations found to improve the pharmacological treatment in psychiatry.
format Online
Article
Text
id pubmed-9104141
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91041412022-05-14 Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders Navarro, Daniela Gasparyan, Ani Navarrete, Francisco Torregrosa, Abraham B. Rubio, Gabriel Marín-Mayor, Marta Acosta, Gabriela B. Garcia-Gutiérrez, Maria Salud Manzanares, Jorge Int J Mol Sci Review The therapeutic benefits of the current medications for patients with psychiatric disorders contrast with a great variety of adverse effects. The endocannabinoid system (ECS) components have gained high interest as potential new targets for treating psychiatry diseases because of their neuromodulator role, which is essential to understanding the regulation of many brain functions. This article reviewed the molecular alterations in ECS occurring in different psychiatric conditions. The methods used to identify alterations in the ECS were also described. We used a translational approach. The animal models reproducing some behavioral and/or neurochemical aspects of psychiatric disorders and the molecular alterations in clinical studies in post-mortem brain tissue or peripheral tissues were analyzed. This article reviewed the most relevant ECS changes in prevalent psychiatric diseases such as mood disorders, schizophrenia, autism, attentional deficit, eating disorders (ED), and addiction. The review concludes that clinical research studies are urgently needed for two different purposes: (1) To identify alterations of the ECS components potentially useful as new biomarkers relating to a specific disease or condition, and (2) to design new therapeutic targets based on the specific alterations found to improve the pharmacological treatment in psychiatry. MDPI 2022-04-26 /pmc/articles/PMC9104141/ /pubmed/35563156 http://dx.doi.org/10.3390/ijms23094764 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Navarro, Daniela
Gasparyan, Ani
Navarrete, Francisco
Torregrosa, Abraham B.
Rubio, Gabriel
Marín-Mayor, Marta
Acosta, Gabriela B.
Garcia-Gutiérrez, Maria Salud
Manzanares, Jorge
Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders
title Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders
title_full Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders
title_fullStr Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders
title_full_unstemmed Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders
title_short Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders
title_sort molecular alterations of the endocannabinoid system in psychiatric disorders
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9104141/
https://www.ncbi.nlm.nih.gov/pubmed/35563156
http://dx.doi.org/10.3390/ijms23094764
work_keys_str_mv AT navarrodaniela molecularalterationsoftheendocannabinoidsysteminpsychiatricdisorders
AT gasparyanani molecularalterationsoftheendocannabinoidsysteminpsychiatricdisorders
AT navarretefrancisco molecularalterationsoftheendocannabinoidsysteminpsychiatricdisorders
AT torregrosaabrahamb molecularalterationsoftheendocannabinoidsysteminpsychiatricdisorders
AT rubiogabriel molecularalterationsoftheendocannabinoidsysteminpsychiatricdisorders
AT marinmayormarta molecularalterationsoftheendocannabinoidsysteminpsychiatricdisorders
AT acostagabrielab molecularalterationsoftheendocannabinoidsysteminpsychiatricdisorders
AT garciagutierrezmariasalud molecularalterationsoftheendocannabinoidsysteminpsychiatricdisorders
AT manzanaresjorge molecularalterationsoftheendocannabinoidsysteminpsychiatricdisorders